Cargando…

Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP)

BACKGROUND: The clinical development of advanced therapy medicinal products (ATMPs), a new class of drugs, requires initial safety studies that deviate from standard non-clinical safety protocols. The study provides a strategy to address the safety aspects of biodistribution and tumorigenicity of AT...

Descripción completa

Detalles Bibliográficos
Autores principales: Zscharnack, Matthias, Krause, Christoph, Aust, Gabriela, Thümmler, Christian, Peinemann, Frank, Keller, Thomas, Smink, Jeske J., Holland, Heidrun, Somerson, Jeremy S., Knauer, Jens, Schulz, Ronny M., Lehmann, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445304/
https://www.ncbi.nlm.nih.gov/pubmed/25990108
http://dx.doi.org/10.1186/s12967-015-0517-x
_version_ 1782373268714422272
author Zscharnack, Matthias
Krause, Christoph
Aust, Gabriela
Thümmler, Christian
Peinemann, Frank
Keller, Thomas
Smink, Jeske J.
Holland, Heidrun
Somerson, Jeremy S.
Knauer, Jens
Schulz, Ronny M.
Lehmann, Jörg
author_facet Zscharnack, Matthias
Krause, Christoph
Aust, Gabriela
Thümmler, Christian
Peinemann, Frank
Keller, Thomas
Smink, Jeske J.
Holland, Heidrun
Somerson, Jeremy S.
Knauer, Jens
Schulz, Ronny M.
Lehmann, Jörg
author_sort Zscharnack, Matthias
collection PubMed
description BACKGROUND: The clinical development of advanced therapy medicinal products (ATMPs), a new class of drugs, requires initial safety studies that deviate from standard non-clinical safety protocols. The study provides a strategy to address the safety aspects of biodistribution and tumorigenicity of ATMPs under good laboratory practice (GLP) conditions avoiding cell product manipulation. Moreover, the strategy was applied on a human ATMP for cartilage repair. METHODS: The testing strategy addresses biodistribution and tumorigenicity using a multi-step analysis without any cell manipulation to exclude changes of test item characteristics. As a safeguard measurement for meeting regulatory expectations, the project design and goals were discussed continuously with the regulatory authority using a staggered scientific advice concept. Subsequently, the strategy was applied to co.don chondrosphere® (huChon spheroid), a tissue-engineered matrix-free ATMP of human normal chondrocytes. In both the biodistribution and tumorigenicity studies, huChon spheroids were implanted subcutaneously into 40 immunodeficient mice. Biodistribution was studied 1 month after implantation. A skin disc containing the huChon spheroid, two surrounding skin rings and selected organs were analyzed by validated, gender-specific, highly-sensitive triplex qPCR and by immunohistochemistry (IHC). RESULTS: No human DNA was detected in distant skin rings and analyzed organs. IHC revealed no direct or indirect indications of cell migration. Tumorigenicity was assessed 6 months after huChon spheroid implantation by palpation, macroscopic inspection, histology and IHC. No mice from the huChon spheroid group developed a tumor at the implantation site. In two mice, benign tumors were detected that were negative for HLA-ABC, suggesting that they were of spontaneous murine origin. CONCLUSIONS: In summary, the presented strategy using a multi-step analysis was confirmed to be suitable for safety studies of ATMPs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0517-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4445304
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44453042015-05-28 Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP) Zscharnack, Matthias Krause, Christoph Aust, Gabriela Thümmler, Christian Peinemann, Frank Keller, Thomas Smink, Jeske J. Holland, Heidrun Somerson, Jeremy S. Knauer, Jens Schulz, Ronny M. Lehmann, Jörg J Transl Med Research BACKGROUND: The clinical development of advanced therapy medicinal products (ATMPs), a new class of drugs, requires initial safety studies that deviate from standard non-clinical safety protocols. The study provides a strategy to address the safety aspects of biodistribution and tumorigenicity of ATMPs under good laboratory practice (GLP) conditions avoiding cell product manipulation. Moreover, the strategy was applied on a human ATMP for cartilage repair. METHODS: The testing strategy addresses biodistribution and tumorigenicity using a multi-step analysis without any cell manipulation to exclude changes of test item characteristics. As a safeguard measurement for meeting regulatory expectations, the project design and goals were discussed continuously with the regulatory authority using a staggered scientific advice concept. Subsequently, the strategy was applied to co.don chondrosphere® (huChon spheroid), a tissue-engineered matrix-free ATMP of human normal chondrocytes. In both the biodistribution and tumorigenicity studies, huChon spheroids were implanted subcutaneously into 40 immunodeficient mice. Biodistribution was studied 1 month after implantation. A skin disc containing the huChon spheroid, two surrounding skin rings and selected organs were analyzed by validated, gender-specific, highly-sensitive triplex qPCR and by immunohistochemistry (IHC). RESULTS: No human DNA was detected in distant skin rings and analyzed organs. IHC revealed no direct or indirect indications of cell migration. Tumorigenicity was assessed 6 months after huChon spheroid implantation by palpation, macroscopic inspection, histology and IHC. No mice from the huChon spheroid group developed a tumor at the implantation site. In two mice, benign tumors were detected that were negative for HLA-ABC, suggesting that they were of spontaneous murine origin. CONCLUSIONS: In summary, the presented strategy using a multi-step analysis was confirmed to be suitable for safety studies of ATMPs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0517-x) contains supplementary material, which is available to authorized users. BioMed Central 2015-05-20 /pmc/articles/PMC4445304/ /pubmed/25990108 http://dx.doi.org/10.1186/s12967-015-0517-x Text en © Zscharnack et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zscharnack, Matthias
Krause, Christoph
Aust, Gabriela
Thümmler, Christian
Peinemann, Frank
Keller, Thomas
Smink, Jeske J.
Holland, Heidrun
Somerson, Jeremy S.
Knauer, Jens
Schulz, Ronny M.
Lehmann, Jörg
Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP)
title Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP)
title_full Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP)
title_fullStr Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP)
title_full_unstemmed Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP)
title_short Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP)
title_sort preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (atmp)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445304/
https://www.ncbi.nlm.nih.gov/pubmed/25990108
http://dx.doi.org/10.1186/s12967-015-0517-x
work_keys_str_mv AT zscharnackmatthias preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp
AT krausechristoph preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp
AT austgabriela preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp
AT thummlerchristian preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp
AT peinemannfrank preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp
AT kellerthomas preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp
AT sminkjeskej preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp
AT hollandheidrun preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp
AT somersonjeremys preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp
AT knauerjens preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp
AT schulzronnym preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp
AT lehmannjorg preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp